Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ROR1R-CAR-T
- Development stage
- Phase 1
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
ROR1R-CAR-T is an autologous chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of ROR1-positive malignancies. The therapy involves the genetic modification of a patient's own T cells to express a CAR targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1). ROR1 is an oncofetal antigen that is highly expressed on the surface of various cancer cells, including those in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma, while being largely absent in healthy adult tissues. By engineering T cells to recognize ROR1, the therapy aims to achieve targeted lysis of malignant cells. This specific candidate was evaluated in clinical trials at the MD Anderson Cancer Center before the program was withdrawn for administrative reasons.
- Other names
- ROR1-specific CAR-T cellsROR-1-specific CAR-T cellsROR 1-specific CAR-T cellsAutologous ROR1-specific CAR-T cellsROR1 CAR-TROR-1 CAR-TROR 1 CAR-T
02
Targets
ROR1 (Receptor tyrosine kinase-like orphan receptor 1)
Beyond the preview
Go deeper on ROR1R-CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ROR1R-CAR-T.